Literature DB >> 15246210

Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure.

Carl C Schimanski1, Jürgen Burg, Markus Möhler, Thomas Höhler, Stephan Kanzler, Gerd Otto, Peter R Galle, Ansgar W Lohse.   

Abstract

BACKGROUND/AIMS: Except for bleeding complications, other serious adverse reactions of coumarin anticoagulants such as hepatotoxicity or skin necrosis are comparatively rare. Nonetheless, a small number of coumarin-induced (sub-) acute liver failures has been published.
METHODS: A retrospective analysis was performed of patients treated for liver disease between 1992 and 2002 at our department to evaluate the incidence, clinical findings and histopathology of coumarin-induced hepatotoxicity.
RESULTS: The retrospective analysis revealed eight cases of phenprocoumon-induced hepatotoxicity, including three cases of (sub-) acute liver failure which resulted in two orthotopic liver transplantations and one fatal outcome. Five patients with phenprocoumon-induced hepatitis recovered well after anticoagulation was switched to another coumarin derivate or subcutaneous low molecular weight heparin. In all patients liver injury was predominantly of an hepatitic type. In the cases of (sub-) acute liver failure massive confluent liver cell necroses were histologically present, whereas among patients without liver failure mild portal to moderate active lobular hepatitis were observed. A retrospective analysis by BfArM (German Federal Institute for Drugs and Medical Devices) revealed 4390 cases of possible phenprocoumon-related adverse reactions since 1990, 2% of which had presented with hepatitis and 0.2% with liver failure.
CONCLUSIONS: Phenprocoumon-induced liver disease is an uncommon complication, which can, however, cause (sub-) acute liver failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246210     DOI: 10.1016/j.jhep.2004.03.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

1.  [Unclear hepatopathy in a patient with atrial fibrillation].

Authors:  C Pennartz; H Schrader; P R Ritter; A Tannapfel; W E Schmidt; J J Meier
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

2.  [Role of vitamin K antagonists from a hepatologist's point of view].

Authors:  G Kneiseler; A Canbay; G Gerken
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

3.  Coumarin embryopathy in an extremely low birth weight infant associated with neonatal hepatitis and ocular malformations.

Authors:  Patrick G Hetzel; René Glanzmann; Pascal W Hasler; Ariane Ladewick; Christoph Bührer
Journal:  Eur J Pediatr       Date:  2006-01-13       Impact factor: 3.183

Review 4.  [Oral anticoagulation using coumarins - an update].

Authors:  Christoph Sucker; Jens Litmathe
Journal:  Wien Med Wochenschr       Date:  2017-06-12

5.  Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Ariola Koci; Francesco Salvo; Antoine Pariente; Maurizio Biselli; Ugo Moretti; Nicholas Moore; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

Review 6.  Acute liver failure: a life-threatening disease.

Authors:  Ali Canbay; Frank Tacke; Johannes Hadem; Christian Trautwein; Guido Gerken; Michael P Manns
Journal:  Dtsch Arztebl Int       Date:  2011-10-21       Impact factor: 5.594

7.  Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study.

Authors:  Antonios Douros; Elisabeth Bronder; Frank Andersohn; Andreas Klimpel; Michael Thomae; Giselle Sarganas; Reinhold Kreutz; Edeltraut Garbe
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

8.  Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation.

Authors:  Alvaro Alonso; Richard F MacLehose; Lin Y Chen; Lindsay Gs Bengtson; Alanna M Chamberlain; Faye L Norby; Pamela L Lutsey
Journal:  Heart       Date:  2017-01-05       Impact factor: 5.994

9.  Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments.

Authors:  Sven Schmiedl; Marietta Rottenkolber; Jacek Szymanski; Werner Siegmund; Marion Hippius; Katrin Farker; Bernd Drewelow; Joerg Hasford; Petra Thürmann
Journal:  Dtsch Arztebl Int       Date:  2013-04-05       Impact factor: 5.594

10.  Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease.

Authors:  Reinhild Klein
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.